Aprepitant Global Buyers List: Comprehensive Guide to Pharmaceutical Importers and Distributors

Aprepitant, a substance P/neurokinin-1 (NK₁) receptor antagonist, has become an indispensable therapeutic agent in oncology care. As the first drug in its class approved for the prevention of chemotherapy-induced nausea and vomiting (CINV), Aprepitant has generated substantial global demand across pharmaceutical supply chains. For manufacturers, distributors, and procurement professionals, understanding the landscape of Aprepitant buyers is essential for market penetration and supply chain optimization. This comprehensive guide presents a detailed Aprepitant global buyers list, market analysis, and strategic insights for stakeholders across the pharmaceutical industry.

Understanding the Aprepitant Market Landscape

The global Aprepitant market has experienced significant growth, driven by rising cancer incidence rates and increasing awareness of CINV management. The Aprepitant API market is projected to grow from approximately USD 405–431 million to USD 535–590 million by 2032, representing a compound annual growth rate (CAGR) of 4.5–4.9%. This growth trajectory underscores the importance of identifying and engaging with key buyers across the pharmaceutical value chain.

Key Market Drivers

Several factors contribute to the robust demand for Aprepitant:

• Rising Oncology Caseloads: National estimates indicate over 3.2 million new cancer cases, supporting repeat antiemetic use
• Clinical Efficacy: Aprepitant augments the antiemetic activity of 5HT3-receptor antagonists and corticosteroids
• Formulation Diversity: Available in capsules, injectable emulsions, and oral tablets across multiple strengths
• Generic Market Expansion: Multiple ANDA approvals have increased market accessibility

Comprehensive Aprepitant Global Buyers List

Based on verified trade data and import-export records, the following represents a curated selection of active Aprepitant buyers across key geographic markets.

North American Buyers

Buyer Name	Location	Key Activities
Heron Therapeutics Inc.	United States	Aprepitant bulk drug procurement; manufacturer of CINVANTI® injectable emulsion
Eversana Life Science Services LLC	United States	Pharmaceutical distribution and procurement
Hepalink USA Inc.	United States	API and finished dosage form sourcing
Sagent	United States	Pharmaceutical procurement
I 3 Pharmaceuticals LLC	United States	Pharmaceutical procurement

European Buyers

Buyer Name	Location	Key Activities
Ethypharm Inc.	France	Aprepitant API procurement
Rontis Hellas	Greece	Extensive pharmaceutical procurement operations
Laboratoires Biogaran	France	Generic pharmaceutical procurement

Asian Buyers

Buyer Name	Location	Key Activities
Zydus Lifesciences Ltd.	India	Aprepitant injectable emulsion procurement
Sun Pharmaceutical Industries Ltd.	India	Pharmaceutical procurement
Alembic Pharmaceuticals Ltd.	India	Pharmaceutical procurement
Alkem Laboratories Corp.	India	Pharmaceutical procurement
Ortiv Q3 Research Pvt Ltd.	India	Aprepitant samples and research procurement
Off Targets Research Pvt Ltd.	India	Aprepitant and related product imports
Chia Tai Tianqing Pharmaceutical	China	Fosaprepitant and related product exports

Other Regions

Buyer Name	Location	Key Activities
R-Pharm Kazakhstan LLP	Kazakhstan	Aprepitant capsules USP procurement
ATN Dis Ticaret Enerji ve San. AS	Turkey	Aprepitant USP procurement
N.P.C.SAC	Peru	Aprepitant capsules procurement
Directorate General of Royal Hosp	Oman	Aprecap (Aprepitant) procurement
Banque Tuniso-Koweitienne	Tunisia	Aprepitant pellets procurement
Vimta Labs Ltd	India	Aprepitant procurement from Spanish suppliers

Major Aprepitant Manufacturers and Suppliers

Understanding the supply side is equally crucial for buyers seeking reliable sourcing partners. The Aprepitant manufacturing landscape includes both innovator and generic producers.

Leading Global Manufacturers

Manufacturer	Headquarters	Key Products
Merck & Co.	United States	Originator of EMEND® capsules
Sandoz	Switzerland	Generic Aprepitant preparations
Glenmark Pharmaceuticals	India	Aprepitant capsules and generics
Torrent Pharmaceuticals	India	Aprepitant capsules multiple strengths
Dr. Reddy’s Laboratories	India	Aprepitant formulations
MSN Laboratories	India	Aprepitant API synthesis
Laurus Labs	India	Aprepitant API
Hetero Drugs	India	Aprepitant API and formulations
Aurobindo Pharma	India	Aprepitant API
Cipla Ltd	India	Aprepitant branded formulations (Aprepit)
Qilu Pharmaceutical	China	Aprepitant preparations
Chia Tai Tianqing Pharmaceutical	China	Fosaprepitant for injection
Shanghai Yingrui Biomedical	China	Aprepitant manufacturing
Viwit Pharmaceuticals	China	Aprepitant API with EDQM and US FDA filings
Sichuan Qingmu Pharmaceutical	China	Aprepitant API
Shandong Anxin Pharmaceutical	China	Aprepitant API
Inke S.A.	Switzerland	Aprepitant API manufacturing
Pharmathen	Greece	Aprepitant API

API Suppliers

The Aprepitant API supply chain involves specialized manufacturers with regulatory credentials including US DMFs, CEPs, and GMP certifications. Key API suppliers include:

• Jubilant Pharmova Limited
• Piramal Pharma
• Viwit Pharmaceuticals Limited
• Solara Active Pharma Sciences
• Divi’s Laboratories
• MSN Laboratories Private Ltd
• Hetero Drugs Ltd
• Wisdom Pharmaceutical Co. Ltd

Procurement Channels and Distribution Networks

Aprepitant reaches end-users through multiple channels, and understanding these pathways is essential for both buyers and suppliers.

Primary Sales Channels

1. Direct Supply to Formulation Sponsors: API manufacturers supply directly to finished-dose manufacturers
2. Pharmaceutical Wholesaler Networks: Distribution through established wholesale channels
3. Contract Development and Manufacturing Organizations (CDMOs): Specialized manufacturing partnerships
4. Government Tenders and Institutional Procurement: Public healthcare procurement

Buyer Types

Procurement teams typically fall into several categories:

• Finished-Dose Manufacturers: Companies producing final pharmaceutical products
• Contract Development and Manufacturing Organizations: Outsourced manufacturing partners
• Formulation Sponsors: Organizations sponsoring drug development
• Research Institutions: Laboratories and research organizations procuring for R&D purposes
• Government Healthcare Agencies: Public sector procurement entities

Strategic Sourcing Considerations for Aprepitant Buyers

For procurement professionals seeking to engage with the Aprepitant global buyers list or establish new supplier relationships, several critical factors warrant attention.

Quality and Regulatory Compliance

Buyers prioritize suppliers with demonstrated quality consistency, audit readiness, and reliable batch support. Key regulatory credentials include:

• US DMF (Drug Master File) : Essential for US market access
• CEP (Certificate of Suitability) : Required for European markets
• GMP Certification: Recognized across multiple markets
• FDA Inspection History: VAI (Voluntary Action Indicated) or NAI (No Action Indicated) status

Supply Chain Resilience

The Aprepitant supply chain requires careful management due to the complexity of API synthesis and regulatory requirements. Supplier switching remains slow due to audit and authorization-update requirements. Procurement teams should evaluate:

• Manufacturing capacity and scalability
• Raw material sourcing and security
• Logistics and cold chain capabilities (for temperature-sensitive formulations)
• Regulatory documentation completeness

Formulation Considerations

Different buyer segments require different formulations:

• Capsules: 40mg, 80mg, 125mg strengths
• Injectable Emulsion: 130mg/18mL (CINVANTI®)
• Oral Tablets: Various strengths

Trade Data and Market Intelligence

For buyers and suppliers seeking to validate market positions or identify new opportunities, trade data provides valuable intelligence. Platforms such as 52wmb.com track hundreds of Aprepitant transactions, with over 451 verified B2B trades tracked across 101 exporters and 154 importers. Recent trade data reveals:

• HS Codes: 30049099 (pharmaceutical preparations), 29349990 (heterocyclic compounds), 300490950000
• CAS Number: 170729-80-3
• Key Export Hubs: India, China, United States
• Key Import Markets: Kazakhstan, United States, France, India

Future Market Outlook

The Aprepitant market presents continued opportunities for buyers and suppliers alike. Key trends shaping the market include:

Growing Oncology Demand

With oncology-care scale supporting repeat antiemetic use, demand for Aprepitant is expected to remain robust. The global nausea and vomiting treatment market, of which Aprepitant is a key component, is projected to grow from US$6.4billiontoUS$6.4billiontoUS 9.8 billion by 2032.

Formulation Innovation

The development of new formulations, including intravenous emulsions like CINVANTI®, expands the addressable market and creates new procurement opportunities.

Generic Market Expansion

Multiple generic approvals have increased competition and accessibility, benefiting buyers through improved pricing and supply options.

Regional Market Growth

Asia-Pacific markets, particularly India and China, continue to expand both as manufacturing hubs and consumption markets.

GADOR S A
MURRY S A
BIOSIDUS SOCIEDAD ANONIMA
LABORATORIO LIBRA SOCIEDAD ANONIMA
NOVARTIS ARGENTINA S A
PFIZER SOCIEDAD DE RESPONSABILIDAD LIMITADA
WARNER LAMBERT DEL URUGUAY S A
LABORATORIOS PHOENIX SAIC Y F
FARMACO URUGUAYO S A
IVAX ARGENTINA SOCIEDAD ANONIMA
ULTRA INTERNATIONAL
KAUSTUBHA SCIENTIFIC RESEARCH LABORATORYPRIVATE LI
GLENMARK PHARMACEUTICALS INC
MYLAN LABORATORIES LIMITED
TUTEUR S A C I F I A
LAZAR S A
ORIENTAL FARMACEUTICA INDUSTRIAL COMERCIAL E INMOBILIARIA SO
ORTIV Q3 RESEARCH PRIVATE LIMITED
PT ORGANON PHARMA INDONESIA TBK
SANDOZ SA DE CV
DROGUERIA LABORATORIOS PHARMEX SAC
INCEPTA PHARMACEUTICALS LIMITED
FEROZSONS LABORATORIES LIMITED
GRAMON BAGO DE URUGUAY S A
LABORATORIO VARIFARMA SA
NAVEGAL LABORATORIES
NORDIC PHARMACEUTICAL COMPANY S A C
OPTIMUS DRUGS PRIVATE LIMITED
TOKYO CHEMICAL INDUSTRY INDIA PRIVATE LIMITED
VMG HEALTH CARE PRODUCTS S A
VMG PHARMA S A
YUSEN LOGISTICS AMERICAS INC
BEACON PHARMACEUTICALS PLC
HONIMELL S A
KHAIRI S A
MINISTERIO DE SALUD
MSD ARGENTINA S R L
VEEDA CLINICAL RESEARCH LIMITED
BIOPROFARMA SA
DR REDDY S LABORATORIES LTD
GLENMARK PHARMACEUTICALS INC USA
GT PHARMA PVT LTD
HEALTHCARE PHARMACEUTICALS LTD
KAUSTUBHA SCIENTIFIC RESEARCH LABORATORY PRIVATE L
MERCK SHARP AND DOHME IA LLC
SIGMA ALDRICH QUIMICA S DE RL DE CV
V M G HEALTHCARE PRODUCTS SOCIEDAD ANONIMA
ANALYTICA CHEMIE INC
G T PHARMA PRIVATE LIMITED
HC LEGD GROUP S A C
JINAY PHARMACEUTICALS PRIVATE LIMITED
M S NAVEGAL LABORATORIES
MERCK SHARP DOHME COMERCIALIZADORA S DE RL DE CV
MERCK SHARP DOHME I A LLC
VIMTA LABS LIMITED
ZENRISE CLINICAL RESEARCH PRIVATE LIMITED
ZYDUS LIFESCIENCES LIMITED
ПРЕДСТАВИТЕЛЬСТВО THESAY PHARMA DRUG STORE L L С
CÔNG TY TNHH DRP INTER
GENOME PHARMACEUTICALS PVT LIMITED
HETERO LABS LIMITED
MERCK SHARP AND DOHME COLOMBIA S A S
MERCK SHARP DOHME PERU S R L
PHARMEVO PRIVATE LIMITED
SIGMA ALDRICH CHEMICALS PRIVATE LIMITED
SKYWIN PHARMACEUTICALS
SLAYBACK PHARMA INDIA LLP
TARGET SA
ТОО МЕМБРАН
AMNEAL PHARMACEUTICALS PRIVATE LIMITED
ASN CORPORATION
CAMBER PHARMACEUTICALS INC
CIPLA LIMITED
CLEARSYNTH LABS LIMITED
DRUG INTERNATIONAL LIMITED
FEROZSONS LABORATORIES LTD
GENOME PHARMACEUTICALS PVT LTD
GLENMARK PHARMACEUTICALS INC US
GOODHEALTH PHARMACEUTICALS PRIVATE LIMITED
LABORATORIOS STEIN SOCIEDAD ANONIMA
LUPIN LIMITED
M S ROTEX PHARMA PVT LIMITED
MSN LABORATORIES PRIVATE LIMITED
PHARMA LORD PVT LTD
PHARMASOL PRIVATE LTD
PHARMASOL PVT LTD
SOMERSET THERAPEUTICS PRIVATE LIMITED
ULTRA LABORATORIOS SA DE CV
UNITED STATES PHARMACOPEIA INDIA PRIVATE LIMITED
UNKNOWN
VMG PHARMA SOCIEDAD ANONIMA
WELMARK PHARMACEUTICALS
ТОО Р ФАРМ КАЗАХСТАН
ASOCIACION VIDA PERU
BIOMEDICAL LIFE SCIENCES
BIOXEL S A
BREAST CARE INTERNATIONAL
CONEPRE SA DE CV
CRENZA PHARMACEUTICALS PRIVATE LIMITED
CÔNG TY TNHH DƯỢC PHẨM HELIOS
DHL INTERNATIONAL NIGERIA LIMITED
DS PHARMA PERU S A C
ESKAYEF PHARMACEUTICALS LIMITED
FEROZSONS LABORATORIES
GENOME PHARMACEUTICAL PVT LTD
GUTIS LIMITADA
HOSPITAL METROPOLITANO S A S
ICU VITA S A
ITAAN PHARMA PRIVATE LIMITED
JUBILANT PHARMOVA LIMITED
JUNTA DE BENEFICENCIA DE GUAYAQUIL
KAUSTUBHA SCIENTIFIC RESEARCH LABORATORY PRIVATE LIMITED
KIREI PHARMA PARAGUAY SA
LABORATORIOS PISA SA DE CV
M S WNSFIELD PHARMACEUTICLS
MANKIND PHARMA LIMITED
MEDSERV AFRICA LIMITED
MORGAN CHEMICALS
MS TORRENT PHARMACEUTICALS LTD
MURLI KRISHNA PHARMA PRIVATE LIMITED
NOVECY PHARMACY CC NP O BOX
NUTRIMED PANAMA S A
OFF TARGETS RESEARCH PRIVATE LIMITED
ONCOPHARM U LTD
ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMI
PHARMAFFILIATES PRIVATE LIMITED
PHARMARAW BANGLADESH PRB
POL AR LTD ENTERPRISE SA DE CV
PPD INTERNATIONAL HOLDINGS INC
QUIMFA S A
RINQUE PHARMA S A
ROTEX PHARMA PRIVATE LTD
SALIX PHARMA LIMITED
SIMSON PHARMA LIMITED
SUCOPEIA REFERENCESTANDARDS OPC PRIVATE LIMITED
SYNERGEN BIO PRIVATE LIMITED
SYNGENE INTERNATIONAL LTD
TOPCLASS ENTERPRISES LLP
TORRENT PHARMACEUTICALS LIMITED
TORRENT PHARMACEUTICALS LTD
URUFARMA S A
URUFARMA SA
VEM ILAC SANAYI VE TICARET ANONIM SIRKETI
WNSFEILD PHARMACEUTICALS
YUSEN LOGISTICS AMERICAS
ZAFA PHARMACEUTICAL LABORATORIES LTD
ПІДПРИЄМСТВО З 100 ІНОЗЕМНОЮ ІНВЕСТИЦІЄЮ АЙК ЮВІА РДС УКРАЇНА 01010 М КИЇВ ВУЛ КНЯЗІВ ОСТРОЗЬКИХ БУД 8 КОРП 7 УКРАЇНА
ПІДПРИЄМСТВО З 100 ІНОЗЕМНОЮ ІНВЕСТИЦІЄЮ АЙК ЮВІА РДС УКРАЇНА 03038 М КИЇВ ВУЛ МИКОЛИ АМОСОВА 12 СОЛОМ ЯНСКИЙ Р ОН УКРАЇНА
ТОО ВИВА ФАРМ

Conclusion

The Aprepitant global buyers list presented in this guide reflects a dynamic and growing pharmaceutical market. From major North American pharmaceutical companies to emerging Asian manufacturers and European distributors, the buyer landscape is diverse and opportunities abound for strategic engagement.

For procurement professionals, success in the Aprepitant market requires:

• Thorough Due Diligence: Verify supplier credentials, regulatory status, and quality systems
• Strategic Relationship Building: Develop long-term partnerships with reliable suppliers
• Market Intelligence: Stay informed about trade data, pricing trends, and regulatory changes
• Supply Chain Optimization: Evaluate multiple sourcing options to ensure continuity of supply

As the global Aprepitant market continues its growth trajectory, understanding the buyer landscape will remain essential for all stakeholders across the pharmaceutical value chain.